In this manuscript we describe a novel antibody-drug conjugate (SGN-LIV1A), targeting the zinc transporter LIV-1 (SLC39A6) for the treatment of metastatic breast cancer. LIV-1 was previously known to be expressed by estrogen receptor-positive breast cancers. In this study, we show that LIV-1 expression is maintained after hormonal therapy in primary and metastatic sites and is also up regulated in triple-negative breast cancers. In 
INTRODUCTION:
In the United States, nearly 300,000 women are diagnosed with breast cancer each year and it is the second leading cause of cancer related mortality in women. Surgery, radiation, hormone therapy and chemotherapy are effective treatments for many, but over 40,000 patients succumb to the disease annually. Breast cancers are classified on the basis of three protein expression markers: estrogen receptor (ER), progesterone receptor (PgR), and the over-expression of the growth factor receptor HER2/neu. Hormonal therapies, including tamoxifen and aromatase inhibitors, can be effective in treating tumors that express the hormone receptors ER and PgR. HER2-directed therapies are useful for tumors that express HER2/neu; these tumors are the only class of breast cancer that is currently eligible for immunotherapy. For these patients, unconjugated antibodies (Herceptin®, Perjeta®) are generally used in combination with chemotherapy. The treatment options for triple-negative breast tumors, those that do not express ER, PgR or HER2/neu, are restricted to chemotherapy, radiation and surgery. Additionally, there are limited effective treatment options available to patients with advanced stage disease with relatively poor survival rates of stage III patients (52%) and significantly worse for stage IV patients (15%). There is clearly a significant need for effective treatments for late stage breast cancer.
Antibody Drug Conjugates (ADCs) are a relatively new treatment modality that takes advantage of the exquisite specificity of monoclonal antibodies by using them to deliver a highly potent cytotoxic agent. The ADC described here is an anti-LIV-1 antibody linked via a cleavable dipeptide linker to monomethylauristatin E (MMAE), the cytotoxic agent.
While there are at least twenty-one ADCs in clinical development (nine auristatin 4 based)(1), only one is approved for use in breast cancer (Kadcyla for HER2+ patient populations).
LIV-1 is a member of the solute carrier family 39; a multi-span transmembrane protein with putative zinc transporter and metalloproteinase activity (2, 3) . It was first identified as an estrogen-induced gene in the breast cancer cell line ZR-75-1 (4) . LIV-1 expression has been linked to epidermal-to-mesenchymal transition (EMT) in both normal vertebrate embryo development (5) and preclinical models (6) (7) (8) leading to malignant progression and metastasis. There is evidence of LIV-1 interacting with the transcription factors STAT3 and Snail to down-regulate expression of E-cadherin to promote EMT (9, 10) . Expression is also associated with lymph node involvement in breast cancer (11) . In addition to breast cancer, it has been detected in other neoplastic tissue types including pancreatic, prostate, breast, melanoma, cervical, and uterine (8, 12, 13) . We evaluated LIV-1 expression in a number of indications using immunohistochemical analysis on tissue biopsies. In addition, we performed quantitative flow cytometry to determine expression of LIV-1 on a panel of cell lines derived from various cancer types. Using a humanized antibody specific for LIV-1 (hLIV22) conjugated to monomethyl auristatin E (14), we demonstrated ADC internalization, in vitro cytotoxicity and anti-tumor activity in in vivo breast and cervical cancer models. Antibody humanization. The murine antibody mLIV22 specifically binds an epitope in the extracellular N-terminus (residues 1-329) of LIV-1. Complementarity-determining region (CDR) grafting was used to generate the humanized anti-LIV-1 antibody hLIV22.
First, the mLIV22 VL CDRs (as defined by Kabat et al. (15) ) were grafted on to the framework regions of human germline exons IGKV2-30 and JK4 obtained from NCBI and fused to human kappa constant domain. Likewise, the complementarity-determining regions of mLIV22 VH were grafted onto the framework regions of human germline exons VH1-2 and JH5 fused to the human IgG1 constant domains. In addition,   framework mutations, F36Y and R46P in the light chain and Y27L, F29I, T30E, S76N and R94V of the heavy chain (numbering scheme of Kabat et al.) , were introduced into the humanized variable domains to enhance antigen-binding activity. The resultant humanized anti-LIV-1 antibody, hLIV22, showed comparable antigen-binding activity to mLIV22 in competition-binding assays using CHO cells transfected with LIV-1.
Immunohistochemistry
Formalin-fixed paraffin-embedded tumor samples were obtained from several sources:
the Cooperative Human Tissue Network, (Rockville, MD, USA); Tissue Solutions (Glasgow, Scotland); NDRI (Philadelphia, PA, USA). Slides were deparaffinized and antigen retrieval was performed using EDTA based buffer. Samples were pre-blocked with non-serum protein block (Dako A/S, Glostrup, Denmark) and primary antibodies, used separately, were incubated for 45 minutes at room temperature. Anti-LIV-1 mAb and isotype control IgG were used at 1 µg/ml. Bond Polymer Refine Detection ( Leica Microsystems, Germany) was used for detection with 3,3′-diaminobenzidine as the substrate for horseradish peroxidase and Bond Polymer Refine Red Detection (Leica Microsystems, Germany) was used for detection with Fast Red as substrate for alkaline phosphatase. Slides were then scored using a qualitative scoring scale (weak 1+, mild 2+, moderate 3+, strong 4+) and images were taken using a Zeiss Axiovert 200M microscope Results are reported as EC 50 , the concentration of compound needed to yield a 50% reduction in viability compared with vehicle-treated cells (control=100%).
PK methods. Six BALB/c mice were dosed IV with 3 mg/kg of SGN-LIV1A. Blood samples were drawn from the saphenous vein from alternating sub-groups of three mice at 5 minutes, 6 and 24 hours, 2, 4, 7, 10 and 14 days post dose and processed to plasma.
Samples were analyzed in a plate based assay as follows: wells were coated overnight with a solution (0.5μg/mL in 0.05M carb/bicarb buffer, pH 9.6) of anti-human IgG kappa antibody (Antibody solutions #AS75-P). After washing with PBS-T, wells were blocked with 1% BSA for 1 hour at room temperature. After washing blocked plates with PBS-T, wells were incubated with samples at room temperature. After 1 hour, plates were washed with PBS-T and incubated for an additional hour with HRP-F(ab')2 goat antihuman IgG Fc-gamma specific (Jackson # 109-036-098). Following a final wash step, TMB substrate was added and incubated for 10 minutes before quenching with 1N HCL, A450 was read and used to calculate serum antibody concentration value of 6.3 ng/ml in a CellTiter Glo (Promega) cytotoxicity assay ( Figure 2B ). In contrast, neither unconjugated parental antibody (Figure 2 ) nor an ADC control hIgGvcMMAE showed substantial cytotoxic activity (EC 50 > 10,000 ng/ml) (data not shown).
In this assay, maximum cytotoxicity was 70%. When comparing a MCF-7 cell lines from different sources we found they had varying concentrations of antigen on the surface of 
PK and in vivo ADC activity study using MCF-7, BR0555 and HeLa tumors. To measure the pharmacokinetic properties of SGN-LIV1A, a single 3 mg/kg dose was administered IV to BALB/C mice; blood samples were taken out to 14 days. The pharmacokinetic properties of the total antibody appear consistent with a two compartment model ( Figure 4A ). The terminal half-life, calculated using non-linear regression, is 6.8 days.
The antitumor activity of SGN-LIV1A was evaluated in xenograft models of breast, and cervical lineage. Two different breast cancer models were explored, one using MCF-7 cells and the other using a patient-derived tissue model. In the MCF-7 breast cancer cell xenograft model, tumor regressions were achieved with four 3mg/kg doses of SGN-LIV1A given every four days (q4dx4; Figure 4B ), well below the mean tolerated dose of 10mg/kg in rodents. While tumor growth delay was seen when dosing with the nontargeted ADC, when comparing it to the 3 mg/kg SGN-LIV1A dose group , P-values compute to <0.05, meeting the threshold of statistical significance difference and indicating both a dose response and immunologic specificity of the targeted therapeutic.
ADC activity in the absence of target has been documented previously on a number of antibody backbones and chemotype combinations (17) (18) (19) . Non-cancer antigen dependent activity is a continuing topic of study and has been attributed to a combination of factors including the enhanced permeability and retention effect of a tumor, ADC and drug linker stability, cellular susceptibility to the delivered cytotoxin, and relative cell permeability of the released drug.
The second breast cancer model (BR0555) was derived from the ER+, PR+ and HER2-infiltrating breast ductal carcinoma tumor from an 86-year-old Caucasian patient 
